Mortality is not associated with paclitaxel-coated devices usage in peripheral arterial disease of lower extremities

Abstract A recent meta-analysis addressed increased risk of death following revascularization with paclitaxel-coated devices in femopopliteal artery. We evaluated differences in all-cause mortality and amputation free survival between peripheral arterial disease (PAD) patients who were treated with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dai Sik Ko, Gi Hwan Bae, Sang Tae Choi, Jaehun Jung, Jin Mo Kang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5385bb32fc7c46a18db1bdfa67fa9bbe
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5385bb32fc7c46a18db1bdfa67fa9bbe
record_format	dspace
spelling	oai:doaj.org-article:5385bb32fc7c46a18db1bdfa67fa9bbe2021-12-02T18:33:51ZMortality is not associated with paclitaxel-coated devices usage in peripheral arterial disease of lower extremities10.1038/s41598-021-97675-92045-2322https://doaj.org/article/5385bb32fc7c46a18db1bdfa67fa9bbe2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97675-9https://doaj.org/toc/2045-2322Abstract A recent meta-analysis addressed increased risk of death following revascularization with paclitaxel-coated devices in femopopliteal artery. We evaluated differences in all-cause mortality and amputation free survival between peripheral arterial disease (PAD) patients who were treated with paclitaxel-coated devices and non-paclitaxel-coated devices. This was retrospective population-based cohort study from the National Health Insurance Service claims in South Korea from 2015 to 2019. Multivariate Cox regression analyses after propensity score matching were applied to identify all-cause mortality and amputation-free survival. After propensity score matching, there were 6090 patients per group. The median follow-up days was 580 days (interquartile range [IQR] 240–991 days) and 433 days (IQR 175–757 days) for the non-paclitaxel-coated device group and paclitaxel-coated device group, respectively. Multivariate analysis adjusted for age, sex, diabetes, hypertension, warfarin, and new oral anticoagulants showed that the mortality rate associated with paclitaxel-coated devices was not significantly higher than non-paclitaxel-coated devices (hazard ratio [HR] 0.992; 95% CI 0.91–1.08). The rate of amputation events was higher in patients with paclitaxel-coated devices than those with non-paclitaxel-coated devices (HR 1.614; 95% CI 1.46–1.78). In this analysis, the mortality rate in patients with PAD was not associated with the use of paclitaxel-coated devices, despite a higher amputation rate.Dai Sik KoGi Hwan BaeSang Tae ChoiJaehun JungJin Mo KangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Dai Sik Ko Gi Hwan Bae Sang Tae Choi Jaehun Jung Jin Mo Kang Mortality is not associated with paclitaxel-coated devices usage in peripheral arterial disease of lower extremities
description	Abstract A recent meta-analysis addressed increased risk of death following revascularization with paclitaxel-coated devices in femopopliteal artery. We evaluated differences in all-cause mortality and amputation free survival between peripheral arterial disease (PAD) patients who were treated with paclitaxel-coated devices and non-paclitaxel-coated devices. This was retrospective population-based cohort study from the National Health Insurance Service claims in South Korea from 2015 to 2019. Multivariate Cox regression analyses after propensity score matching were applied to identify all-cause mortality and amputation-free survival. After propensity score matching, there were 6090 patients per group. The median follow-up days was 580 days (interquartile range [IQR] 240–991 days) and 433 days (IQR 175–757 days) for the non-paclitaxel-coated device group and paclitaxel-coated device group, respectively. Multivariate analysis adjusted for age, sex, diabetes, hypertension, warfarin, and new oral anticoagulants showed that the mortality rate associated with paclitaxel-coated devices was not significantly higher than non-paclitaxel-coated devices (hazard ratio [HR] 0.992; 95% CI 0.91–1.08). The rate of amputation events was higher in patients with paclitaxel-coated devices than those with non-paclitaxel-coated devices (HR 1.614; 95% CI 1.46–1.78). In this analysis, the mortality rate in patients with PAD was not associated with the use of paclitaxel-coated devices, despite a higher amputation rate.
format	article
author	Dai Sik Ko Gi Hwan Bae Sang Tae Choi Jaehun Jung Jin Mo Kang
author_facet	Dai Sik Ko Gi Hwan Bae Sang Tae Choi Jaehun Jung Jin Mo Kang
author_sort	Dai Sik Ko
title	Mortality is not associated with paclitaxel-coated devices usage in peripheral arterial disease of lower extremities
title_short	Mortality is not associated with paclitaxel-coated devices usage in peripheral arterial disease of lower extremities
title_full	Mortality is not associated with paclitaxel-coated devices usage in peripheral arterial disease of lower extremities
title_fullStr	Mortality is not associated with paclitaxel-coated devices usage in peripheral arterial disease of lower extremities
title_full_unstemmed	Mortality is not associated with paclitaxel-coated devices usage in peripheral arterial disease of lower extremities
title_sort	mortality is not associated with paclitaxel-coated devices usage in peripheral arterial disease of lower extremities
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/5385bb32fc7c46a18db1bdfa67fa9bbe
work_keys_str_mv	AT daisikko mortalityisnotassociatedwithpaclitaxelcoateddevicesusageinperipheralarterialdiseaseoflowerextremities AT gihwanbae mortalityisnotassociatedwithpaclitaxelcoateddevicesusageinperipheralarterialdiseaseoflowerextremities AT sangtaechoi mortalityisnotassociatedwithpaclitaxelcoateddevicesusageinperipheralarterialdiseaseoflowerextremities AT jaehunjung mortalityisnotassociatedwithpaclitaxelcoateddevicesusageinperipheralarterialdiseaseoflowerextremities AT jinmokang mortalityisnotassociatedwithpaclitaxelcoateddevicesusageinperipheralarterialdiseaseoflowerextremities
_version_	1718377920052854784

Mortality is not associated with paclitaxel-coated devices usage in peripheral arterial disease of lower extremities

Ejemplares similares